mechlorethamine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1647 | 51-75-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 15, 1949 | FDA | RECORDATI RARE |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site pruritus | 531.47 | 54.24 | 79 | 633 | 807 | 2356566 |
| Application site pain | 402.70 | 54.24 | 67 | 645 | 1459 | 2355914 |
| Application site erythema | 385.66 | 54.24 | 63 | 649 | 1217 | 2356156 |
| Pruritus | 322.97 | 54.24 | 103 | 609 | 43237 | 2314136 |
| Application site discolouration | 256.88 | 54.24 | 36 | 676 | 224 | 2357149 |
| Skin discolouration | 233.04 | 54.24 | 52 | 660 | 5368 | 2352005 |
| Erythema | 220.08 | 54.24 | 68 | 644 | 25091 | 2332282 |
| Application site irritation | 212.17 | 54.24 | 33 | 679 | 449 | 2356924 |
| Skin irritation | 190.23 | 54.24 | 35 | 677 | 1350 | 2356023 |
| Therapy non-responder | 181.93 | 54.24 | 46 | 666 | 8058 | 2349315 |
| Application site vesicles | 135.18 | 54.24 | 22 | 690 | 402 | 2356971 |
| Skin burning sensation | 124.48 | 54.24 | 26 | 686 | 1930 | 2355443 |
| Application site dryness | 102.61 | 54.24 | 14 | 698 | 68 | 2357305 |
| Blister | 101.59 | 54.24 | 28 | 684 | 6743 | 2350630 |
| Disease progression | 91.20 | 54.24 | 32 | 680 | 17063 | 2340310 |
| Skin hyperpigmentation | 87.05 | 54.24 | 17 | 695 | 893 | 2356480 |
| Application site discharge | 86.38 | 54.24 | 12 | 700 | 68 | 2357305 |
| Dry skin | 74.86 | 54.24 | 22 | 690 | 6630 | 2350743 |
| Application site exfoliation | 72.30 | 54.24 | 11 | 701 | 126 | 2357247 |
| Rash | 71.90 | 54.24 | 39 | 673 | 59519 | 2297854 |
| Cutaneous T-cell lymphoma | 62.91 | 54.24 | 11 | 701 | 311 | 2357062 |
| Application site rash | 61.85 | 54.24 | 12 | 700 | 607 | 2356766 |
| Application site inflammation | 60.08 | 54.24 | 9 | 703 | 92 | 2357281 |
| Skin lesion | 57.29 | 54.24 | 16 | 696 | 4009 | 2353364 |
| Application site warmth | 55.62 | 54.24 | 8 | 704 | 60 | 2357313 |
| Large intestine polyp | 54.99 | 54.24 | 12 | 700 | 1086 | 2356287 |
| Skin disorder | 54.27 | 54.24 | 15 | 697 | 3616 | 2353757 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site pruritus | 555.45 | 77.04 | 79 | 752 | 257 | 1745693 |
| Application site erythema | 490.45 | 77.04 | 77 | 754 | 557 | 1745393 |
| Application site pain | 400.82 | 77.04 | 66 | 765 | 660 | 1745290 |
| Pruritus | 368.91 | 77.04 | 115 | 716 | 23107 | 1722843 |
| Skin irritation | 245.63 | 77.04 | 44 | 787 | 736 | 1745214 |
| Therapy non-responder | 229.53 | 77.04 | 60 | 771 | 6206 | 1739744 |
| Erythema | 218.11 | 77.04 | 69 | 762 | 14119 | 1731831 |
| Application site irritation | 217.62 | 77.04 | 33 | 798 | 178 | 1745772 |
| Application site vesicles | 197.13 | 77.04 | 30 | 801 | 166 | 1745784 |
| Skin burning sensation | 155.59 | 77.04 | 30 | 801 | 754 | 1745196 |
| Blister | 138.92 | 77.04 | 37 | 794 | 4055 | 1741895 |
| Application site discolouration | 136.45 | 77.04 | 20 | 811 | 81 | 1745869 |
| Disease progression | 132.09 | 77.04 | 50 | 781 | 17213 | 1728737 |
| Skin discolouration | 131.39 | 77.04 | 33 | 798 | 2863 | 1743087 |
| Cutaneous T-cell lymphoma | 118.71 | 77.04 | 21 | 810 | 321 | 1745629 |
| Application site discharge | 110.78 | 77.04 | 15 | 816 | 28 | 1745922 |
| Dry skin | 104.54 | 77.04 | 29 | 802 | 3683 | 1742267 |
| Application site burn | 90.33 | 77.04 | 14 | 817 | 88 | 1745862 |
| Skin exfoliation | 85.73 | 77.04 | 26 | 805 | 4509 | 1741441 |
| Second primary malignancy | 84.07 | 77.04 | 19 | 812 | 1040 | 1744910 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01AA05 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Nitrogen mustard analogues |
| FDA MoA | N0000000236 | Alkylating Activity |
| FDA EPC | N0000175558 | Alkylating Drug |
| MeSH PA | D000477 | Alkylating Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D018906 | Antineoplastic Agents, Alkylating |
| MeSH PA | D002619 | Chemical Warfare Agents |
| MeSH PA | D007509 | Irritants |
| MeSH PA | D009676 | Noxae |
| MeSH PA | D011042 | Poisons |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chronic lymphoid leukemia, disease | indication | 92814006 | |
| Chronic myeloid leukemia | indication | 92818009 | DOID:8552 |
| Polycythemia vera | indication | 109992005 | |
| Hodgkin's disease | indication | 118599009 | |
| Non-Hodgkin's lymphoma | indication | 118601006 | |
| Mycosis fungoides | indication | 118618005 | |
| Malignant tumor of lung | indication | 363358000 | |
| Primary cutaneous T-cell lymphoma | indication | 400122007 | |
| Pericardial Malignant Effusions | indication | ||
| Peritoneal Malignant Effusions | indication | ||
| Pleural Malignant Effusions | indication | ||
| Amyloidosis | contraindication | 17602002 | DOID:9120 |
| Hyperuricemia | contraindication | 35885006 | DOID:1920 |
| Acute infectious disease | contraindication | 63171007 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Secondary malignant neoplasm of bone marrow | contraindication | 94217008 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Bone marrow depression | contraindication | 307762000 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Granulocytopenic disorder | contraindication | 417672002 | |
| Chemotherapy-Induced Hyperuricemia | contraindication |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 5.7 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 0.016% BASE | VALCHLOR | HELSINN | N202317 | Aug. 23, 2013 | RX | GEL | TOPICAL | 8501819 | March 7, 2026 | ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY |
| EQ 0.016% BASE | VALCHLOR | HELSINN | N202317 | Aug. 23, 2013 | RX | GEL | TOPICAL | 7872050 | July 8, 2029 | ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 0.016% BASE | VALCHLOR | HELSINN | N202317 | Aug. 23, 2013 | RX | GEL | TOPICAL | Aug. 23, 2020 | TOPICAL TREATMENT OF STAGE 1A AND 1B MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN-DIRECTED THERAPY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| DNA | DNA | OTHER | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019808 | VUID |
| N0000147897 | NUI |
| C0025033 | UMLSCUI |
| D04872 | KEGG_DRUG |
| 50D9XSG0VR | UNII |
| 586 | INN_ID |
| 372692002 | SNOMEDCT_US |
| 29156002 | SNOMEDCT_US |
| 4019808 | VANDF |
| 6674 | RXNORM |
| d01339 | MMSL |
| 387071000 | SNOMEDCT_US |
| 29634 | MMSL |
| 004816 | NDDF |
| 4033 | PUBCHEM_CID |
| CHEBI:28925 | CHEBI |
| CHEMBL427 | ChEMBL_ID |
| DB00888 | DRUGBANK_ID |
| 55-86-7 | SECONDARY_CAS_RN |
| CHEMBL1201001 | ChEMBL_ID |
| D008466 | MESH_DESCRIPTOR_UI |
| 7218 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| VALCHLOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-016 | GEL | 0.01 g | TOPICAL | NDA | 17 sections |
| VALCHLOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69639-120 | GEL | 0.01 g | TOPICAL | NDA | 17 sections |